A Phase 1b, Open-Label Study of Eftozanermin Alfa in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

被引：0
|
作者：
Richardson, Paul G.
Polepally, Akshanth R.
Motwani, Monica
Mu, Yunming
Salman, Zeena
Penugonda, Sudhir
Moreau, Philippe
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-137037
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma
    Jacob P. Laubach
    Sascha A. Tuchman
    Jacalyn M. Rosenblatt
    Constantine S. Mitsiades
    Kathleen Colson
    Kelly Masone
    Diane Warren
    Robert A. Redd
    Dena Grayson
    Paul G. Richardson
    Blood Cancer Journal, 11
  • [2] Phase 1 open-label study of panobinostat, lenalidomide, bortezomib plus dexamethasone in relapsed and relapsed/refractory multiple myeloma
    Laubach, Jacob P.
    Tuchman, Sascha A.
    Rosenblatt, Jacalyn M.
    Mitsiades, Constantine S.
    Colson, Kathleen
    Masone, Kelly
    Warren, Diane
    Redd, Robert A.
    Grayson, Dena
    Richardson, Paul G.
    BLOOD CANCER JOURNAL, 2021, 11 (02)
  • [3] An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma
    Alodhaibi, Ibrahim
    Ailawadhi, Sikander
    Burbano, Gabriel P.
    O'Brien, Patrick J.
    Buadi, Francis K.
    Hayman, Suzanne
    Kumar, Shaji K.
    Gonsalves, Wilson I.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (05): : 298 - 304
  • [4] A Phase 1b Study of Venetoclax Combined with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Moreau, Philippe
    Chanan-Khan, Asher
    Roberts, Andrew W.
    Agarwal, Amit B.
    Facon, Thierry
    Kumar, Shaji
    Touzeau, Cyrille
    Cordero, Jaclyn
    Ross, Jeremy
    Munasinghe, Wijith
    Jia, Jia
    Salem, Ahmed H.
    Leverson, Joel
    Maciag, Paulo
    Verdugo, Maria
    Harrison, Simon J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E16 - E16
  • [5] A PHASE 1B STUDY OF VENETOCLAX COMBINED WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Moreau, P.
    Chanan-Khan, A.
    Roberts, A. W.
    Agarwal, A. B.
    Facon, T.
    Kumar, S.
    Touzeau, C.
    Cordero, J.
    Ross, J.
    Munasinghe, W.
    Jia, J.
    Salem, A. H.
    Leverson, J.
    Maciag, P.
    Verdugo, M.
    Harrison, S. J.
    HAEMATOLOGICA, 2017, 102 : 169 - 169
  • [6] A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF BORTEZOMIB AND DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Jakubowiak, A.
    Offidani, M.
    Pegourie, B.
    De La Rubia, J.
    Garderet, L.
    Laribi, K.
    Bosi, A.
    Marasca, R.
    Laubach, J.
    Mohrbacher, A.
    Carella, A. M.
    Singhal, A. K.
    Tsao, L. C.
    Lynch, M.
    Bleickardt, E.
    Jou, Y. M.
    Palumbo, A.
    HAEMATOLOGICA, 2015, 100 : 2 - 2
  • [7] PHASE 1B STUDY OF VENETOCLAX COMBINED WITH BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Moreau, P.
    Chanan-Khan, A.
    Roberts, A. W.
    Agarwal, A.
    Facon, T.
    Kumar, S.
    Touzeau, C.
    Diehl, S.
    Cordero, J.
    Ross, J.
    Munasinghe, W.
    Zhu, M.
    Salem, A. H.
    Leverson, J.
    Maciag, P.
    Verdugo, M.
    Harrison, S. J.
    HAEMATOLOGICA, 2016, 101 : 81 - 82
  • [8] Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma
    Chari, Ajai
    Lonial, Sagar
    Suvannasankha, Attaya
    Fay, Joseph W.
    Arnulf, Bertrand
    Ifthikharuddin, Jainulabdeen J.
    Qin, Xiang
    Masterson, Tara
    Nottage, Kerri
    Schecter, Jordan M.
    Ahmadi, Tahamtan
    Weiss, Brendan
    Krishnan, Amrita
    Lentzsch, Suzanne
    BLOOD, 2015, 126 (23)
  • [9] Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma.
    Siegel, David
    Jagannath, Sundar
    Lonial, Sagar
    Dimopoulos, Meletios A.
    Graef, Thorsten
    Pietrangelo, Dina
    Lupinacci, Lisa
    Reiser, David
    Rizvi, Syed
    Anderson, Kenneth C.
    BLOOD, 2009, 114 (22) : 1497 - 1497
  • [10] Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study
    Lonial, Sagar
    San-Miguel, Jesus F.
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Blade, Joan
    Benboubker, Lotfi
    Oriol, Albert
    Arnulf, Bertrand
    Chari, Ajai
    Pineiro, Luis
    Wu, Kaida
    Wang, Jianping
    Doshi, Parul
    Schecter, Jordan
    Moreau, Philippe
    BLOOD, 2017, 130
12345